By Market & Region

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber is strengthening its position in Japan's highly competitive mini-vehicle segment as it begins supplying its fuel-efficient BluEarth-FE AE30 tire as original equipment for Nissan's new Roox, launched in 2025 and equipped in selected grades with 155/65R14 75S fitments.

Fuel-efficient OE tire for Japan's next-generation kei car

The OE deal places Yokohama's BluEarth-FE AE30 at the heart of one of Japan's most important volume segments: compact, city-focused mini-vehicles. Built under the BluEarth brand concept of being "environmentally, human, and socially friendly," the BluEarth-FE AE30 is positioned as a standard tire that balances rolling resistance, safety and comfort - critical factors for OEMs seeking to meet fuel-efficiency regulations and customer expectations in urban use.

SHERIDAN, WYOMING - December 24, 2025 - UAE operator du has signed a three-year agreement with Huawei after deploying what the companies describe as the world's first 25Gbps E-band microwave link to support a 5G-Advanced (5G-A) site rollout, aiming to boost capacity and consistency where fiber backhaul is limited.

From "site upgrades" to backhaul strategy
5G-Advanced pushes more traffic through the radio layer, but the customer experience still hinges on the transport network behind it. du framed the partnership as a joint innovation framework-not just procurement-designed to keep pace with surging data transmission demand while accelerating scalable 5G-A coverage across the UAE, including areas where fiber deployment is slower or impractical.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.

SHERIDAN, WYOMING - December 19, 2025 - Bristol Myers Squibb (BMS) has struck a potential $1B-plus partnership with Harbour BioMed to collaborate on next-generation multi-specific antibody programs, underscoring how China-based innovation is increasingly shaping global biologics dealmaking.

Deal scope and economics in brief
BMS will pay $90 million upfront to work with Harbour on developing and advancing multi-specific antibody therapies, with additional development and commercial milestones that could total up to $1.035 billion. The partners did not disclose how many programs are covered, nor did they specify initial targets, indications, or therapeutic areas.

For business development teams and portfolio planners, the structure reflects a familiar "platform-plus-programs" model: BMS buys early discovery leverage and optionality, while Harbour positions itself for milestone upside and downstream royalties if programs progress.

SHERIDAN, WYOMING - December 19, 2025 - Voyager Therapeutics is laying off 30 employees after partner Novartis discontinued two undisclosed discovery-stage programs under the companies' gene therapy collaboration, underscoring how quickly platform-driven R&D bets can be reprioritized even inside marquee pharma partnerships.

Commercial partnerships can shift overnight
Voyager disclosed last month that Novartis had stepped away from two early programs tied to their ongoing relationship, without naming the assets or detailing the rationale. The biotech framed the change as manageable, stating that Novartis' decision will "not impact Voyager's cash runway guidance." Still, the workforce reduction signals that operational resets often follow partnership scope changes-especially when programs are preclinical and the near-term value is concentrated in a smaller set of advancing assets.

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.

SHERIDAN, WYOMING - December 19, 2025 - Merck said the EMA's CHMP has recommended approval of an expanded European indication for WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH), a move that-if confirmed by the European Commission-could broaden use to include WHO Functional Class (FC) IV patients and strengthen the product's positioning around morbidity and mortality benefit.

SHERIDAN, WYOMING - December 19, 2025 - Merck Animal Health says the U.S. Food and Drug Administration (FDA) has granted conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution), positioning the pour-on as a new systemic parasiticide option for U.S. beef operations and replacement dairy heifers facing New World screwworm (Cochliomyia hominivorax) larvae (myiasis) risk and cattle fever tick (Rhipicephalus microplus) pressure.

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

SHERIDAN, WYOMING - December 19, 2025 - As illegal and abusive drone activity increasingly threatens people and critical infrastructure-especially near air traffic assets-industry association UAV DACH is urging European and national policymakers to establish clearer rules, shared visibility, and coordinated capabilities for effective drone detection and defense across Europe.

SHERIDAN, WYOMING - December 19, 2025 - Henry Schein One says adoption of its cloud-native Dentrix Ascend platform is accelerating as dental groups and DSOs move away from legacy practice management systems to standardize operations, reduce administrative friction, and embed AI into everyday workflows.

Cloud migration becomes a scaling decision, not an IT project
Across U.S. dentistry, consolidation and multi-location growth are forcing operators to treat practice management software as core infrastructure. Henry Schein One reported that nearly 600 practices migrated from alternative systems to Ascend over the past 12 months, adding to the broader Dentrix customer base of more than 48,000 practices using Dentrix technology for clinical, operational, and financial workflows. The company also said monthly Ascend installations more than doubled year over year as practices transitioned away from legacy setups.

SHERIDAN, WYOMING - December 19, 2025 - MYTHIC, an overseas high-tech enterprise focused on anti-drone technologies, is expanding its profile as a low-altitude security provider by combining drone detection, intelligent identification, precise tracking, and efficient suppression into integrated defense systems designed for high-value, high-risk environments.

From point solutions to "intelligent airspace security barriers"
MYTHIC frames its core proposition as end-to-end protection against unauthorized UAV activity-built to perform in complex operational settings where disruption is not an option. The company says its solutions are deployed in airports, ports, petrochemical bases, hospitals, schools, luxury hotels, shopping malls, key public safety protection sites, and government office areas, reflecting buyer demand for layered protection that can be tuned to site constraints.

SHERIDAN, WYOMING - December 18, 2025 - Motor Presse Stuttgart is kicking off a year-long anniversary cycle for its flagship automotive media brand auto motor und sport, marking 80 years of publishing with a premium-format XXL issue and a 2026 editorial program designed to deepen reach across print and digital channels.

An anniversary issue designed as a premium brand statement
Motor Presse Stuttgart is launching the jubilee year with an oversized special edition of auto motor und sport featuring a refined additional cover, larger format, and an expanded 232-page scope. The move signals a deliberate positioning strategy: in a fragmented media environment, special-interest publishers are increasingly using premium "event issues" to reinforce brand authority, extend dwell time, and create high-impact inventory for partners.

SHERIDAN, WYOMING - December 18, 2025 - Citroën is using the 2026 Brussels Motor Show as a strategic showcase for its renewed electric portfolio and brand positioning, placing compact EV innovation, comfort-led SUVs and electric motorsport on the radar of European dealers, fleet buyers and mobility partners.

Brussels stand becomes a live lab for Citroën's electrification strategy

At the show, which opens to the public on 9 January 2026, Citroën is building a stand that mirrors its current transformation: colourful, modern and highly focused on accessible, electrified mobility. Alongside the world premiere of the ELO concept, visitors will see the new C5 Aircross as the brand's flagship SUV, the Ami in its new Dark Side edition, and a Formula E single-seater that signals Citroën's next era in electric motorsport.

For B2B stakeholders, the line-up illustrates how Citroën is repositioning its range around:

SHERIDAN, WYOMING - December 18, 2025 - Citroën has appointed Aline Germain as the brand's new marketing lead, effective January 1, 2026, as the automaker continues to sharpen its global positioning across electric, hybrid, and mainstream mobility segments within the Stellantis portfolio.

Leadership change signals renewed focus on brand equity and go-to-market execution
Citroën said Germain will become responsible for Marketing Citroën from 1 january 2026, replacing Federico Goyret, who has been appointed to a position to be announced later. The company said Germain will report to Citroën Brand CEO Xavier Chardon, placing the role at the center of strategy-to-market coordination as Citroën competes for attention in a crowded European and global volume market.

SHERIDAN, WYOMING - December 18, 2025 - A new B2B-focused nautical event, the Napoli Boat Show (NBS), will debut from March 18-22, 2026 at Marina di Stabia in Castellammare di Stabia, positioning itself as a "Boutique Boat Show" built around a simple commercial premise: every boat on display is ready to sail, and sea trials are the norm rather than the exception.

A "Ready-to-Sea" exhibition model built for sales conversations
Unlike traditional dockside showcases, NBS is designed to reverse exhibition logic by putting on-water testing at the center of the buying process. The show's proposition is that there is a material difference between viewing a vessel moored at the quay and experiencing it underway-especially in a setting that allows shipowners and professional buyers to evaluate handling, comfort, and performance in real conditions.

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.

SHERIDAN, WYOMING - December 15, 2025 - HoldCo Asset Management says Comerica shareholders should vote against the proposed merger with Fifth Third at a special meeting scheduled for January 6, 2026, arguing the transaction undervalues Comerica and that rejecting the deal could improve shareholder outcomes with limited downside.

Activist investor challenges deal process and governance safeguards
HoldCo Asset Management, a Florida-based investment firm managing approximately $2.6 billion in regulatory assets under management, said it holds beneficial ownership of approximately 1.6% of Comerica's outstanding common stock and released a presentation titled "Why We Recommend Voting AGAINST The Proposed Merger and Our Litigation Update." The firm's case centers on how the transaction was negotiated and whether the board's process delivered maximum value for shareholders.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences (NASDAQ: HURA) has provided a corporate update following a recent $15.6 million equity financing, detailing near-term milestones across its Phase 3 IFx-2.0 program in Merkel cell carcinoma, its VISTA-inhibiting antibody TBS-2025 in AML, and its Delta Opioid Receptor (DOR)-focused conjugate platform aimed at overcoming resistance to cancer immunotherapy.

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA) announced that Kintara's REM-001 clinical trial in ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety, a contractual milestone that is expected to trigger distribution of TuHURA common stock to eligible contingent value right (CVR) holders.